Aytu BioPharma Dividends and Buybacks
Dividend criteria checks 0/6
Aytu BioPharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-40.9%
Buyback Yield
| Total Shareholder Yield | -40.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
Nov 15
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Nov 01It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Jun 20Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Jun 14US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AYTU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AYTU's dividend payments have been increasing.
Dividend Yield vs Market
| Aytu BioPharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AYTU) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (AYTU) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate AYTU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AYTU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AYTU's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AYTU has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:26 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aytu BioPharma, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Nazibur Rahman | Maxim Group |